Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

NCT ID: NCT00868296

Last Updated: 2010-05-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to provide additional information on safety and tolerability after multiple does of pantoprazole. Only patients who successfully completed the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) are eligible to participate in this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose

Group Type ACTIVE_COMPARATOR

pantoprazole

Intervention Type DRUG

High dose

Group Type ACTIVE_COMPARATOR

pantoprazole

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pantoprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Successful completion of the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) Study.

Exclusion Criteria

* Patients requiring chronic use of warfarin, carbamepazine, or phenytoin.
Minimum Eligible Age

1 Day

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wyeth

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Belgium, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Germany, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Netherlands, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Poland, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For South Africa, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Australia, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For France, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Italy, [email protected]

Trial Manager

Role: PRINCIPAL_INVESTIGATOR

For Switzerland, [email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phoenix, Arizona, United States

Site Status

Loma Linda, California, United States

Site Status

Oakland, California, United States

Site Status

Orange, California, United States

Site Status

Sacramento, California, United States

Site Status

San Diego, California, United States

Site Status

New Haven, Connecticut, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Gainesville, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Sunrise, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Honolulu, Hawaii, United States

Site Status

Boise, Idaho, United States

Site Status

Chicago, Illinois, United States

Site Status

Park Ridge, Illinois, United States

Site Status

Lexington, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Flint, Michigan, United States

Site Status

Omaha, Nebraska, United States

Site Status

Camden, New Jersey, United States

Site Status

New Brunswick, New Jersey, United States

Site Status

Newark, New Jersey, United States

Site Status

Albany, New York, United States

Site Status

Brooklyn, New York, United States

Site Status

New York, New York, United States

Site Status

The Bronx, New York, United States

Site Status

Valhalla, New York, United States

Site Status

Durham, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Portland, Oregon, United States

Site Status

Danville, Pennsylvania, United States

Site Status

Memphis, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Dallas, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Burlington, Vermont, United States

Site Status

Richmond, Virginia, United States

Site Status

Morgantown, West Virginia, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Brisbane, , Australia

Site Status

Edegem, , Belgium

Site Status

Leuven, , Belgium

Site Status

Vancouver, British Columbia, Canada

Site Status

Ottawa, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Sainte-Foy, Quebec, Canada

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Bochum, , Germany

Site Status

Osnabrück, , Germany

Site Status

Potsdam, , Germany

Site Status

Brescia, , Italy

Site Status

Napoli, , Italy

Site Status

Roma, , Italy

Site Status

Rotterdam, , Netherlands

Site Status

Bydgoszcz, , Poland

Site Status

Krakow, , Poland

Site Status

Lublin, , Poland

Site Status

Panorama, CPT, South Africa

Site Status

Pietermaritzburg, KwaZulu-Natal, South Africa

Site Status

Durban, , South Africa

Site Status

Overport, , South Africa

Site Status

Pretoria, , South Africa

Site Status

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Canada France Germany Italy Netherlands Poland South Africa Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3001B3-335

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Role of Pepsin Assay in Wheezy Infants
NCT02685436 COMPLETED PHASE4
Optimal Dosing of Omeprazole in Neonates
NCT01657578 COMPLETED PHASE2